Category: Investment, Biotech, Biodefense
Biotech/Biodefense Stock News; RedChip Research Issues Research Update on Aethlon Medical (OTCBB: AEMD)
Visit this company: www.aethlonmedical.com
ORLANDO, Fla. - April 20, 2011 (Investorideas.com newswire) RedChip Research(TM), a division of RedChip Companies, Inc., today announced it has issued a research update on Aethlon Medical, Inc. (OTCBB: AEMD), a company developing therapeutic filtration devices to address infectious disease and cancer.
To receive a complimentary copy of the RedChip Research Report for AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=357
To learn more about Aethlon Medical, Inc. visit http://www.redchip.com/visibility/investor.asp?symbol=AEMD
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.
"Discovering Tomorrow's Blue Chips Today"(TM)
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
None of the reports issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security nor do they constitute investment advice. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Information contained in the research reports is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. Aethlon Medical, Inc. (AEMD) is a client of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip Companies. AEMD has agreed to pay RedChip Companies, Inc. a fee of 250,000 shares of Rule 144 stock for twelve (12) months of RedChip Visibility Program and six (6) months of investor awareness services. RedChip Visibility Program services include the preparation of the equity research report(s). The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. The equity research report(s) are not a recommendation of a solicitation to purchase or sell any security, nor do they constitute investment advice. Investor awareness services and programs are designed to help companies communicate their investment characteristics. These services may include investor conferences, digital and print distribution of AEMD investor-related materials or services, and radio programming. None of the profiles issued by RedChip Companies, Inc., constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein.
RedChip Companies Inc.
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.